Why the study?
Does the renal vasodilator response to irbesartan correlate with BMI in subjects with Type 2 diabetes?
Population
12 subjects with Type 2 diabetes on a low sodium diet, with a wide range of body mass index (BMI).
Comparison
Irbesartan 150 mg (single dose). vs Baseline measurements (pre-intervention).
Design
Cohort
Follow-up
4 hours
Authors
Loading...
No immediate change to irbesartan use by BMI; extends evidence linking obesity to intrarenal RAS activation in diabetes.
Does the renal vasodilator response to irbesartan correlate with BMI in subjects with Type 2 diabetes?
In patients with Type 2 diabetes, higher BMI strongly correlates with an enhanced renal vasodilator response to irbesartan, suggesting obesity activates the intrarenal renin system.
Price et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: